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Abstract: We aimed to evaluate the expression of amine oxidase proteins in breast cancer and
their clinical implications. We performed immunohistochemical staining of amine oxidase proteins
(LOX, lysyl oxidase, AOC3, amine oxidase, MAOA, monoamine oxidase A, MAOB, monoamine
oxidase B). Based on their hormone receptors, such as estrogen receptor (ER) and progesterone
receptor (PR), human epidermal growth factor receptor 2 (HER-2), and Ki-67 immunohistochemical
staining, breast cancer was divided into four molecular subtypes: luminal A, luminal B, HER-2 type,
and triple-negative breast cancer (TNBC). Luminal A was observed in 380 cases (49.4%), luminal
B in 224 (29.1%), HER-2 type in 68 (8.8%), and TNBC in 98 (12.7%). Stromal AOC3, MAO-A, and
MAO-B expression varied according to molecular subtypes. Stromal AOC3 expression was high in
luminal B and HER-2 type and MAO-A expression was high in luminal A and luminal B (p < 0.001).
MAO-B expression was higher in TNBC than in other subtypes (p = 0.020). LOX positivity was
associated with high histological grade (p < 0.001) and high Ki-67 labeling index (LI) (p = 0.009),
and stromal AOC3 positivity was associated with high histological grade (p = 0.001), high Ki-67
LI (p < 0.001), and HER-2 positivity (p = 0.002). MAO-A positivity was related to low histological
grade (p < 0.001), ER positivity, PR positivity (p < 0.001), and low Ki-67 LI (p < 0.001). In univariate
analysis, MAO-A positivity was related to short disease-free survival in HER-2 type (p = 0.013), AOC3
negativity was related to short disease-free survival and overall survival in ER-positive breast cancer,
PR-positive breast cancer, HER-2-negative breast cancer, and lymph node metastasis. In conclusion,
the expression of amine oxidase proteins varies depending on the molecular subtype of breast cancer.
Stromal AOC3 expression was high in luminal B and HER-2 type, and MAO-A expression was high
in luminal A and luminal B.
Keywords: amine oxidase; breast cancer; estrogen receptor; human epidermal growth factor receptor
2; progesterone receptor
1. Introduction
Amine oxidase is an enzyme that catalyzes the oxidative cleavage of alkylamine into aldehydes
and ammonia. Amine oxidase is divided into two groups according to cofactor: lysyl oxidase (LOX)
and primary-amine oxidase, copper containing 2 and 3 (AOC2 and AOC3) that are proteins with
copper as a cofactor, and monoamine oxidases (MAO), consisting of enzymes MAO-A and MAO-B,
with falvin as a cofactor [1]. Amine oxidase participates in various metabolic pathways and is involved
in cell differentiation, cell growth, wound healing, detoxification, and cell signaling [2]. Some amine
oxidases have been reported to be involved in regulating cancers; LOX has played an important role
in colorectal cancer cell dissemination in the bone marrow [3], and expression of AOC3 is associated
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with cancer prognosis in various tumors [4–6]. Altered MAO-A expression is associated with the
poor prognosis of cancer and demonstrates a correlation with prostate tumorigenesis and cancer
metastasis [7], and MAO-B is known to exhibit high expression in gliomas [8]. Therefore, amine
oxidase can be expected to affect cancer biology.
Breast cancer is a representative heterogeneous tumor, with various clinical, histological, molecular,
and genetic signatures, and research to classify breast cancer with similar properties is ongoing. Breast
cancer has been divided into normal, basal-like, luminal A, luminal B, and human epidermal growth
factor receptor 2 (HER-2) type by gene profiling analysis [9–11]. In addition to their classification by
gene profiling analysis, was divided breast cancer according to estrogen receptor (ER), progesterone
receptor (PR), and HER-2 into another subgroup, triple-negative breast cancer (TNBC). TNBC is defined
when immunohistochemistry for ER, PR, HER-2, and FISH for HER-2 is negative [12]. These molecular
aspects can differ even in metabolic features because of the differences in histological findings, clinical
findings, therapeutic response, and prognosis. Basal-like type and TNBC are reported to exhibit
high expression of GLUT-1 and CAIX [13,14], and glutaminolysis-related proteins are reported to be
highly expressed in HER-2 type breast cancer [15]. These findings support the relationship between
metabolism and molecular subtype. However, research on the activity of amine oxidase proteins in
breast cancer has not yet been conducted. This study aimed to investigate the expression and clinical
implication of amine oxidase proteins in human breast cancer.
2. Results
2.1. Patient Characteristics
Among 770 cases, luminal A was observed in 380 cases (49.4%), luminal B in 224 cases (29.1%),
HER-2 in 68 cases (8.8%), and TNBC in 98 cases (12.7%). There was a difference in age (p = 0.040),
histological grade (p < 0.001), nodal metastasis status (p = 0.028), and Ki-67 labeling index (LI) (p < 0.001)
with respect to the molecular subtype. High histological grade and Ki-67 LI were associated with TNBC,
high percentage of old-aged patients was associated with HER-2, and increased nodal metastasis was
associated with luminal A (Table 1).
Table 1. Clinicopathological characteristics of patients by breast cancer molecular subtypes.
Parameter Total(n = 770) (%)
Luminal A
(n = 380) (%)
Luminal B
(n = 224) (%)
HER-2
(n = 68) (%)
TNBC
(n = 98) (%) p-Value
Age (years) 0.040
≤50 463 (60.1) 234 (61.6) 144 (64.3) 32 (47.1) 53 (54.1)
>50 307 (39.9) 146 (38.4) 80 (35.7) 36 (52.9) 45 (45.9)
Histological grade <0.001
I/II 559 (72.6) 354 (93.2) 135 (60.3) 37 (54.4) 33 (33.7)
III 211 (27.4) 26 (6.8) 89 (39.7) 31 (45.6) 65 (66.3)
Tumor stage 0.158
T1 433 (56.2) 228 (60.0) 122 (54.5) 35 (51.5) 48 (49.0)
T2/T3 337 (43.8) 152 (40.0) 102 (45.5) 33 (48.5) 50 (51.0)
Nodal metastasis 0.028
Absent 460 (59.7) 213 (56.1) 133 (59.4) 43 (63.2) 71 (72.4)
Present 310 (40.3) 167 (43.9) 91 (40.6) 25 (36.8) 27 (27.6)
Estrogen-receptor status <0.001
Negative 196 (25.5) 9 (2.4) 21 (9.4) 68 (100.0) 98 (100.0)
Positive 574 (74.5) 371 (97.6) 203 (90.6) 0 (0.0) 0 (0.0)
Progesterone-receptor status <0.001
Negative 263 (34.2) 48 (12.6) 49 (21.9) 68 (100.0) 98 (100.0)
Positive 507 (65.8) 332 (87.4) 175 (78.1) 0 (0.0) 0 (0.0)
HER-2 status <0.001
Negative 609 (79.1) 380 (100.0) 131 (58.5) 0 (0.0) 98 (100.0)
Positive 161 (20.9) 0 (0.0) 93 (41.5) 68 (100.0) 0 (0.0)
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Table 1. Cont.
Parameter Total(n = 770) (%)
Luminal A
(n = 380) (%)
Luminal B
(n = 224) (%)
HER-2
(n = 68) (%)
TNBC
(n = 98) (%) p-Value
Ki-67 LI (%) <0.001
≤14 457 (59.4) 380 (100.0) 49 (21.9) 17 (25.0) 11 (11.2)
>14 313 (40.6) 0 (0.0) 175 (78.1) 51 (75.0) 87 (88.8)
Duration of clinical follow-up
(months, mean ± SD) 71.8 ± 21.7 72.9 ± 20.1 71.6 ± 21.6 64.1 ± 25.3 73.5 ± 24.4 0.019
TNBC: triple negative breast cancer; HER-2: Human growth factor receptor-2. LI: labeling index. Bold represents
p < 0.05.
2.2. Differential Expression of Amine Oxidase in Different Tumor Subtypes
Investigation of the expression of the amine oxidase family of proteins according to the molecular
subtype of breast cancer revealed differences in the expression of stromal AOC3, MAO-A, and MAO-B;
high expression of stromal AOC3 in luminal B and HER-2-type breast cancers; and high MAO-A
expression in luminal A and luminal B (p < 0.001). MAO-B expression was higher in TNBC than that
in other proteins (p = 0.020) (Table 2, and Figures 1 and 2).
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Figure 2. Differential expression of amine i ase in different tumor subtypes. The expression of
stromal AOC3, MAO-A, and MAO-B; high expression of stromal AOC3 in luminal B and HER-2-type
breast cancers; and high MAO-A expression in luminal A and luminal B (p < 0.001). MAO-B expression
was higher in TNBC than that in other proteins (p = 0.020).
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Table 2. Expression of the amine oxidase according to breast cancer subtypes.
Parameter Total(n = 770) (100%)
Luminal A
(n = 380) (49.4%)
Luminal B
(n = 224) (29.1%)
HER-2
(n = 68) (8.8%)
TNBC
(n = 98) (12.7%) p-Value
LOX 0.178
Negative 413 (53.6) 218 (57.4) 113 (50.4) 31 (45.6) 51 (52.0)
Positive 357 (46.4) 162 (42.6) 111 (49.6) 37 (54.4) 47 (48.0)
AOC3 0.199
Negative 178 (23.1) 84 (22.1) 49 (21.9) 14 (20.6) 31 (31.6)
Positive 592 (76.9) 296 (77.9) 175 (78.1) 54 (79.4) 67 (68.4)
AOC3 (S) <0.001
Negative 681 (88.4) 352 (92.6) 182 (81.3) 58 (85.3) 89 (90.8)
Positive 89 (11.6) 28 (7.4) 42 (18.8) 10 (14.7) 9 (9.2)
MAOA <0.001
Negative 546 (70.6) 229 (60.3) 168 (75.0) 59 (86.8) 90 (91.8)
Positive 224 (29.1) 151 (39.7) 56 (25.0) 9 (13.2) 8 (8.2)
MAOB 0.020
Negative 658 (85.5) 337 (88.7) 189 (84.4) 57 (83.8) 75 (76.5)
Positive 112 (14.5) 43 (11.3) 35 (15.6) 11 (16.2) 23 (23.5)
MAOB (S) 0.075
Negative 648 (84.2) 331 (87.1) 178 (79.5) 55 (80.9) 84 (85.7)
Positive 122 (15.8) 49 (12.9) 46 (20.5) 13 (19.1) 14 (14.3)
S: stroma. Bold represents p < 0.05.
2.3. Correlation of the Expression of Amine Oxidase Proteins in Breast Cancer
A statistically significant correlation was observed among amine oxidase proteins: LOX–AOC3
(r = 0.238, p < 0.001), LOX–AOC3 (S) (r = 0.144, p < 0.001), LOX–MAO-B (S) (r = 0.160, p < 0.001), AOC3
(S)–MAO-B (S) (r = 0.121, p < 0.001), AOC3–AOC3 (S) (r = 0.160, p < 0.001), and MAO-B–MAO-B (S)
(r = 0.245, p < 0.001) (Table 3).
Table 3. Correlation of the expression of amine oxidase proteins breast cancer.
Parameters LOX AOC3 AOC3 (S) MAOA MAOB MAOB (S)
LOX
Correlation coefficient 0.238 0.144 0.001 0.060 0.160
p-value <0.001 <0.001 0.982 0.098 <0.001
AOC3
Correlation coefficient 0.160 0.087 −0.001 0.052
p-value <0.001 0.016 0.978 0.147
AOC3 (S)
Correlation coefficient −0.035 −0.034 0.121
p-value 0.335 0.347 <0.001
MAOA
Correlation coefficient 0.060 −0.043
p-value 0.095 0.233
MAOB
Correlation coefficient 0.245
p-value <0.001
2.4. Correlation between the Expression of Amine Oxidase and Clinicopathological Characteristics
LOX positivity was associated with a high histological grade (p < 0.001) and high Ki-67 LI
(p = 0.009). Stromal AOC3 positivity was associated with a high histological grade (p = 0.001), high
Ki-67 LI (p < 0.001), and HER-2 positivity (p = 0.002). MAO-A positivity was associated with a low
histological grade (p < 0.001), ER positivity (p < 0.001), PR positivity (p < 0.001), and low Ki-67 LI
(p < 0.001) (Figure 3).
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LOX positivity was associated with a high histological gr de (p < 0.001) and high Ki-67 LI (p = 0.009).
Stromal AOC3 positivity was associated with a high histological grade (p = 0.001), high Ki-67 LI
(p < 0.001), and HER-2 positivity (p = 0.002). MAO-A positivity was associated with a low histological
grade (p < 0.001), estrogen receptor (ER) positivity (p < 0.001), PR positivity (p < 0.001), and low Ki-67
LI (p < 0.001).
2.5. Functional Analysis Using STRING Database
Using “Mutual Exclusivity” function, 3 significant gene pairs with mutually exclusive alteration
were identified (ERBB2-PGR, AOC3-ERBB2, MKI67-ESR1) and 1 gene pair with con rrent alteration
(AOC3-MAOA) in this set. The response to hormone stimulus a d the response to lipids include
Lox and MAOB together with ESR1, suggestive of he prese ce of common activator of estrogen
positive type of breast cancer (Fi ure 4). As the tumor fraction f TCGA was at least 60%, the
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expression assessed may be originated from the tumor, not from the stroma. In addition, we used
the “Enrichments” function of cBioPortal and acquired other gene sets that are significantly increased
in samples with alteration of studied markers. With this gene set, we performed pathway analysis
using PANTHER database. Interestingly, transforming growth factor beta-activated receptor activity
(GO: 0005024) and transforming growth factor beta binding (GO: 0050431), and regulation of vascular
endothelial growth factor receptor signaling pathway (GO: 0030947) were over-represented in this gene
set, suggestive of potential involvement of studied pathway in the epithelial-mesenchymal transition
and angiogenesis of breast cancer (Supplementary data).
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Figure . Functional analysis using STRING database. Using “Mutual Excl sivity” f nction, 3 significant
gene pairs with mutually exclusive alteration were identified (ERBB2-PGR, AOC3-ERBB2, MKI67-ES 1)
and 1 gene pair with concurrent alteratio (AOC3-MAOA). The esponse to hormone stimulus (red)
and the response to lipids (blue) include Lox and MAOB together with ESR1, suggestive of the presence
of common activator of estrog n positive type of breast cancer.
2.6. Effect of the Expression of Amine Oxidase on Survival
The analysis of the effect of amine oxidase protein expression on breast cancer prognosis was not
significant in the univariat analysis (Table 4). However, in the subgroup analysis, MAO-A po itivity
wa associ ted wit short DFS in HER-2-type r ast cancer (p = 0.013), luminal A was as ociated with
short OS (p = 0.047). In ER-positive breast cancer, AOC3 negativity was associated with short DFS and
OS (p = 0.013 and p = 0.037, respectively). AOC3 negativity was associated with short DFS and OS
in PR-positive cancer (p = 0.028 and p = 0.012, respectively). In HER-2-negative breast cancer, AOC3
negativity was associated with short DFS and OS (p = 0.026 and p = 0.037, respectively), and in the
breast cancer showing lymph node metastasis, AOC3 negativity was associated with short DFS and
OS (p = 0.038 and p = 0.012, respectively) (Figure 5).
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Figure 5. Effect of the expression of amine oxidase on survival in breast cancer. MAO-A positivity was
associated with short DFS in HER-2-type breast cancer (a) (p = 0.013), luminal A was associated with
short OS (b) (p = 0.047). In ER-positive breast cancer, AOC3 negativity was associated with short DFS
(c) and short OS (d) (p = 0.013 and p = 0.037, respectively). AOC3 negativity was associated with short
DFS (e) and short OS (f) in PR-positive cancer (p = 0.028 and p = 0.012, respectively). In HER-2-negative
breast cancer, AOC3 negativity was associated with short DFS (g) and short OS (h) (p = 0.026 and
p = 0.037, respectively), and in the breast cancer showing lymph node metastasis, AOC3 negativity was
associated with short DFS (i) and short OS (j) (p = 0.038 and p = 0.012, respectively).
Table 4. Univariate analysis of the impact of amine oxidase expression on breast cancer patient prognosis
by log-rank test.
Parameter Number of Patients/
Recurrence/Death
Disease-Free Survival Overall Survival
Mean Survival
(95% CI) Months p-Value
Mean Survival
(95% CI) Months p-Value
LOX 0.413 0.859
Negative 413/16/30 103 (102–105) 101 (99–103)
Positive 357/10/25 105 (104–107) 102 (100–104)
AOC3 0.062 0.050
Negative 178/10/19 103 (100–106) 100 (97–103)
Positive 592/16/36 105 (104–106) 103 (101–104)
AOC3 (S) 0.522 0.558
Negative 681/24/50 105 (103–106) 102 (101–103)
Positive 89/2/5 106 (103–108) 104 (100–107)
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Table 4. Cont.
Parameter Number of Patients/
Recurrence/Death
Disease-Free Survival Overall Survival
Mean Survival
(95% CI) Months p-Value
Mean Survival
(95% CI) Months p-Value
MAOA 0.484 0.074
Negative 546/20/45 104 (103–106) 101 (100–103)
Positive 224/6/10 106 (104–107) 104 (102–106)
MAOB 0.890 0.106
Negative 658/22/43 105 (104–106) 103 (101–104)
Positive 112/4/12 105 (102–107) 100 (95–104)
MAOB (S) 0.126 0.674
Negative 648/19/45 105 (104–106) 102 (101–104)
Positive 122/7/10 103 (99–106) 102 (99–105)
3. Discussion
We investigated the expression of amine oxidase proteins based on molecular subtypes of breast
cancer. We observed that stromal AOC3 was highly expressed in luminal B and HER-2-type breast
cancer, and MAO-A was highly expressed in luminal A and luminal B. To the best of our knowledge,
ours is the first study to present the results of AOC3 expression in breast cancer. No previous
study has examined the expression of AOC3 in breast cancer tissues, and the expression of AOC3 in
breast cancer stroma has not yet been reported. AOC3 is considered to be a marker distinguishing
myofibroblasts from activated fibroblasts, as reported in a previous study [16]. The subgroup exhibiting
a myofibroblastic phenotype in a cancer-associated fibroblast (CAF) has been reported to cause tumor
cell motility [17] and collagen fiber elongation [18]. In addition, the stromal cell expressing AOC3
influences tumor biology. There is a difference in the expression of CAF proteins depending on
the molecular subtype of breast cancer. In particular, most CAF proteins are reported to be highly
expressed in HER-2-type breast cancer stroma, which is consistent with our study [19]. CAF gene
expression differs with respect to the molecular subtype of breast cancer [20]. The expression of
the gene involved in cancer cell migration was higher in the CAF of HER-2-type breast cancer than
that in TNBC and ER-positive type cancer [20]. AOC3 is a marker to determine the myofibroblast
phenotype of CAF, and the myofibroblast promotes cancer cell migration and invasion [21]. Therefore,
high expression of AOC3 can be associated with high expression of the gene involved in cancer cell
migration in HER-2-positive breast cancer stroma.
MAO-A was highly expressed in luminal-type cancer, and the expression of MAO-A was reported
to be increased with chemically-induced mammary cancer in rats, in previous studies [22,23]; however,
the expression of MAO-A using human breast cancer tissue has not yet been reported. Since all three
ER receptors (α, β, and γ) increased the transcription of MAO-A [24], the high expression of MAO-A
with ER-positive luminal-type breast cancer is explained in our study. In a study analyzing gene chip
data from human cancer tissue, it was reported that MAO-A expression decreased in 95.4% of human
cancers compared to that in normal tissue; research on human breast cancer and human basal-like
breast cancer demonstrated decreased expression of MAO-A compared with that in normal tissue [25].
However, it is difficult to compare the present study with the previous one, since our study does
not analyze the comparison with normal tissue but demonstrates the difference in breast cancer by
molecular subtype.
MAO-B was highly expressed in human TNBC in our study. However, there have been no studies
evaluating MAO-B expression in human TNBC tissue. Previous studies using breast cancer cell lines
have reported that estrogen-related receptor (ERR) increases MAO-B expression, while ER decreases
ERR-induced MAO-B expression [26]. Therefore, high expression of MAO-B in TNBC, which is
negative for ER, can be predicted. Overexpressing ERRα in MDA-MB-231, which is a TNBC breast
cancer cell line, increases MAO-B expression, which supports the results of our study [27].
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In the present study, LOX positivity was associated with high histological grade and high Ki-67 LI.
A previous study reported that LOX mRNA level was higher in breast cancer tissue than normal tissue;
however, there was no difference in LOX mRNA level between ER-positive breast cancer and TNBC,
which is consistent with our findings [28]. A previous study reported that LOX is highly expressed in
highly invasive cancers and metastatic breast cancer cell lines [29,30]. In addition, LOX expression
increases in breast cancer cells under hypoxic conditions [28]. It is well known that breast cancers with
a high Ki-67 LI have a high proliferative potential and are likely to be in hypoxic conditions. Therefore,
the expression of LOX can be expected to be high in aggressive breast cancers with a high histological
grade and high Ki-67 LI.
In this study, AOC negativity with ER-positive breast cancer, PR-positive breast cancer, HER-2-
negative breast cancer, and breast cancer with lymph node metastasis demonstrated an association
with short DFS and short OS. Studies analyzing breast cancer tissue and benign tissue with proteomic
analysis showed that AOC3 expression was decreased in breast cancer [31], suggesting the possibility
that the stage-specific marker, AOC3, may affect the prognosis of breast cancer. However, AOC3
overexpression is associated with poor prognosis of astrocytoma, which is different from the results in
this study [4]. AOC3 is an endothelial adhesion protein, and is involved in cancer cell extravasation
of cells that invade the endothelial cell layer of other organs and tissues, and AOC3 is reported to
be associated with poor prognosis [32,33]. However, in previous studies on colon and gastric cancer,
serum AOC3 level was higher in cancer patients than in healthy subjects, and a low preoperative level
of serum AOC3 indicated poor prognosis [5,6]. This finding supports the results of our study that
AOC negativity indicated poor prognosis.
Although it is not possible to evaluate the exact reason for the association of low serum AOC3
level with poor prognosis, tumor immunity can be presented as a possible mechanism. Serum AOC3
promotes lymphocyte binding in endothelial cells and can lead to lymphocyte accumulation in tumor
vesicles [34]. This in turn, activates tumor-infiltrating lymphocytes (TIL) to induce a protective
local immune response. Therefore, tumor proliferation can be suppressed. In the absence of AOC3
expression in breast cancer, we can assume possibilities of a poor prognosis by low protective, local
immune responses. However, further studies investigating this association are needed.
The clinical significance of this study is that amine oxidase proteins can be used for possible
targeted therapeutic treatments in breast cancer. In various cancers, the LOX inhibitor [35–38] and
MAO-A inhibitors [39–41] have been studied for tumor suppression, and these studies are crucial in
breast cancer as well.
In conclusion, the expression of amine oxidase proteins varied depending on the molecular
subtype of breast cancer. Stromal AOC3 expression was high in luminal B and HER-2-type breast
cancer, and MAO-A expression was high in luminal A and luminal B. Expression of amine oxidase
proteins, especially AOC3, is associated with prognosis in breast cancer subgroups.
4. Materials and Methods
4.1. Patient Selection and Histological Evaluation
We analyzed 770 cases diagnosed as invasive ductal carcinoma (IDC), not otherwise specified
(NOS), at Severance Hospital between January 2006 and December 2008. Patients who underwent
neoadjuvant chemotherapy or hormonal therapy were excluded from the study.
This study was approved by the Institutional Review Board of Yonsei University Severance
Hospital (Approval number: 4-2016-0832, Approved in 14 November, 2016). IRB exempted the
informed consent from patients. The sections were stained with hematoxylin and eosin (H&E) and all
cases were retrospectively reviewed by one breast pathologist (Koo JS). Histological grade was assessed
using the Nottingham grading system [42]. Clinicopathologic parameters evaluated in each case
included patient age at initial diagnosis, lymph node metastasis, tumor recurrence, and patient survival.
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4.2. Tissue Microarray
A representative area showing tumor and tumor stroma was selected on an H&E-stained slide,
and a corresponding spot was marked on the surface of the paraffin block. Using a biopsy needle,
the selected area was punched out, and a 3-mm tissue core was transferred to a 6 × 5 recipient block.
Two tissue cores of invasive tumor were extracted to minimize extraction bias. Each tissue core was
assigned a unique tissue microarray location number that was linked to a database containing other
clinicopathologic data.
4.3. Immunohistochemistry
Detailed information of used antibodies in immunohistochemistry is listed in Table 5.
All immunohistochemistry was performed with formalin-fixed, paraffin-embedded tissue sections
using an automatic immunohistochemistry staining device (Benchmark XT, Ventana Medical System,
Tucson, AZ, USA). Briefly, 5-µm-thick formaldehydefixed paraffin-embedded tissue sections were
transferred onto adhesive slides and dried at 62 ◦C for 30 min. Standard heat epitope retrieval was
performed for 30 min in ethylene diamine tetraacetic acid, pH 8.0, in the autostainer. The samples
were then incubated with primary antibodies. After incubation with primary antibodies (amine
oxidase related markers (LOX, AOC3, MAO-A, and MAO-B), molecular subtype related markers
(ER, PR, HER-2, and Ki-67)), the sections were subsequently incubated with biotinylated anti-mouse
immunoglobulins, peroxidase-labeled streptavidin (LSAB kit, DakoCytomation, Glostrup, Denmark),
and 3,30-diaminobenzidine. Negative control samples were processed without the primary antibody.
Positive control tissue was used as per the manufacturer’s recommendation and slides were
counterstained with Harris hematoxylin.
Table 5. Source, clone, and dilution of antibodies.
Antibody Company Clone Dilution
Amine oxidase
lysyl oxidase (LOX) Abcam, Cambridge, UK Polyclonal 1:100
amine oxidase (AOC3) Abcam, Cambridge, UK Polyclonal 1:1000
monoamine oxidase A Abcam, Cambridge, UK EPR7101 1:100
monoamine oxidase B Abcam, Cambridge, UK Polyclonal 1:100
Molecular subtype-related proteins
ER Thermo Scientific, San Diego, CA, USA SP1 1:100
PR DAKO, Glostrup, Denmark PgR 1:50
HER-2 DAKO, Glostrup, Denmark Polyclonal 1:1500
Ki-67 Abcam, Cambridge, UK SP6 1:100
4.4. Interpretation of Immunohistochemical Staining
All immunohistochemical markers were accessed by light microscopy. A cut-off value of 1%
or more positively stained nuclei was used to define ER and PR positivity [43]. HER-2 staining
was analyzed according to the American Society of Clinical Oncology (ASCO)/College of American
Pathologists (CAP) guidelines using the following categories: 0 = no immunostaining; 1+ = weak
incomplete membranous staining, less than 10% of tumor cells; 2+ = complete membranous staining,
either uniform or weak in at least 10% of tumor cells; and 3+ = uniform intense membranous staining
in at least 30% of tumor cells [44]. HER-2 immunostaining was considered positive when strong (3+)
membranous staining was observed, whereas cases with 0 to 1+ were regarded as negative. Cases
showing 2+ HER-2 expression were evaluated for HER-2 amplification by FISH. Ki-67 labeling index
(LI) was defined as the percentage of total number of tumor cells with nuclear staining.
Immunohistochemical markers were accessed by light microscopy. The stained slides were
reviewed and evaluated semi-quantitatively [45]. Tumor and stromal cell staining were assessed as
0, negative or weak immunostaining in <1% of the tumor/stroma; (1) focal expression in 1–10% of
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tumor/stroma; (2) positive in 11–50% of tumor/stroma; and (3) positive in 51–100% of tumor/stroma.
This evaluation was performed over the entire tumor area and indicated as negative for 0 and positive
for cases with a score > 1.
4.5. Tumor Phenotype Classification
In this study, we classified breast cancer phenotypes according to the immunohistochemistry
results for ER, PR, HER-2, Ki-67 LI and fluorescent in situ hybridization (FISH) results for HER-2 as
follows [46]: Luminal A type, ER or/and PR positive, HER-2 negative and Ki-67 LI < 14%; Luminal B
type, (HER-2 negative) ER or/and PR positive, HER-2 negative and Ki-67 LI ≥ 14%; (HER-2 positive)
ER or/and PR positive and HER-2 overexpressed or/and amplified; HER-2 overexpression type, ER and
PR negative and HER-2 overexpressed or/and amplified; TNBC type: ER, PR, and HER-2 negative.
4.6. Functional Analysis Using STRING Database
We analyzed functional association of studied proteins using STRING database. As expression
profile related genes are not available, we only were able to assessed functional enrichments using
“Analysis” function of the platform. Adding other 10 first order proteins and second 10 order proteins
did not change the clusters with fair local clustering coefficient of 0.799. As the available information
of expression is limited in this study set, we investigated gene expression pattern of studied markers
in 982 TCGA sequenced provisional samples via www.cbioportal.org by using “Mutual Exclusivity”
function and the ‘Enrichments’ function. We performed pathway analysis using PANTHER database.
4.7. Statistical Analysis
Data were analyzed using SPSS for Windows, Version 23.0 (SPSS Inc., Chicago, IL, USA).
For determination of statistical significance, Student’s t and Fisher’s exact tests were used for
continuous and categorical variables, respectively. In the case of analyzing data with multiple
comparisons, a corrected p-value with the application of the Bonferroni multiple comparison procedure
was used. Statistical significance was set to p < 0.05. Kaplan-Meier survival curves and log-rank
statistics were employed to evaluate time to tumor recurrence, disease-free survival (DFS) and
overall survival (OS). Multivariate regression analysis was performed using the Cox proportional
hazards model.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/12/2775/s1.
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